The specific aim of this project is to synthesize proprietary drugs to treat schistosomiasis, leishmaniasis, and trypanosomiasis parasitic diseases. The basis for this proposal is related to two technical assumptions that should greatly reduce the toxicity of antimony while enhancing the eff icacy of the drugs. There are scattered references from the published literature suggesting these improvements.Approximately 20 new trivalent antimony compounds will be prepared. Primarily they will be derivatives of carboxylic acids, hydroxy-carboxylic acids, and carbohydrates.Besides reducing toxicity, another badly needed improvement in the therapeutic administration of antiparasitic drugs is to have the drugs taken orally rather than by inconvenient and painful subcutaneous or intramuscular injections. The structural modifications achieved by this project should result in more stable and bioavailable antimony compositions administered orally.Institute Of Allergy And Infectious Diseases
